Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
about
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisBarriers to preventive therapy for breast and other major cancers and strategies to improve uptakeChemoprevention of cancer: current evidence and future prospectsPreventive treatments for breast cancer: recent developmentsChallenging and complex decisions in the management of the BRCA mutation carrierClinical utilities of aromatase inhibitors in breast cancerNovel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and DithiobenzanilidesAtypical hyperplasia of the breast--risk assessment and management options.What Matters to Women When Making Decisions About Breast Cancer Chemoprevention?Development of an electronic breast pathology database in a community health system.Risk-benefit profiles of women using tamoxifen for chemoprevention.Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'Treatment and prognosis for retrograde cervical lymph node metastases in breast cancer.An Effective Multimodal Curriculum to Teach Internal Medicine Residents Evidence-Based Breast Health.Hormone Replacement Therapy, Likely Neither Angel Nor Demon.Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.Acceptance and adherence to chemoprevention among women at increased risk of breast cancerBreast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot StudyChemoprevention for Breast Cancer.Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).Recent incidence and descriptive epidemiological survey of breast cancer in Saudi ArabiaUsing Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition.Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancerNonsurgical management of fibroadenoma and virginal breast hypertrophyBenign breast disease, mammographic breast density, and the risk of breast cancer.Statins and Breast Cancer: Future Directions in Chemoprevention.Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention.Skeletal manifestations of treatment of breast cancer on premenopausal women.Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ.The selective estrogen receptor modulators in breast cancer prevention.Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy.Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.Clinical utility of a Web-enabled risk-assessment and clinical decision support program.The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care.NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.
P2860
Q26773464-00AAA941-E8BE-4597-AEC8-9E24FF51E95EQ26774593-FEB3D82C-182E-48CD-BFD9-E351D241987EQ27000363-1EB7A70F-322A-44A4-9EDF-83BB4ADEF5C2Q27025375-593D5E82-84F1-49F0-BFE4-52AF08B90413Q27026559-480CC19D-11D7-4618-AFBA-98D9AF6E587BQ28081168-A20448B2-9BE8-49FE-B62D-F3EFE28A1D4EQ28552026-61E31A8F-5362-4630-A311-ED13A672604BQ30301033-C95394DE-5068-4686-AFF4-57DA183E4CC4Q33910927-58DBB283-B010-4792-B28C-E460FA2397E6Q34077507-7F3A3FD4-B021-4C84-B597-178D006A4110Q34974865-60E12523-1054-4EF1-9500-F6590CF7430CQ35130901-67086B8B-6FDA-42F0-A153-2E93DD30FC7AQ35648989-D80B0F26-5E28-43AA-A449-3EB0AF626D2FQ35770373-1EB19E1B-44BD-4A6B-B8D3-ED95E7119652Q35780539-B6A3EB3B-C671-4387-B9AC-1DC98056FADAQ35812120-72A55D57-F721-4839-B38E-FA911CF5C0A5Q35854935-32B1D1F7-73BD-4C7E-B306-94850073C1DEQ35866151-AA41CAF6-B887-4757-BD5D-CF98ED80AEFDQ35998680-C5FA9B62-D816-480D-979A-AF2F8B4983F0Q36048136-49C0DF8A-BE75-40AA-BAA1-C96F64D935A4Q36117814-771A9BB9-BD19-4704-B1D9-82099ADC4E0CQ36210259-D9FC867B-A7CD-49AF-8563-49B546A4C33DQ36255311-C165C988-DCD8-442F-9636-5C261C05FEACQ36258270-C87B54B8-31AF-4C52-A759-2B360DE270D9Q36368070-8EB92517-F502-4157-A88A-40826B7CAA78Q36934323-8909AE00-21F1-4F8C-B976-5AB29F30A515Q36996076-D14E52B7-C91D-4963-8318-F6A3B0D6EF86Q37021220-2BDD56E2-9679-49C0-88DD-DBFE9F30357BQ37119810-0AD17E8C-8FEF-4080-B64F-ABC33E7459B7Q37270445-B3587283-E76D-4B28-ACD2-D310A8EE2FC8Q37681706-569FA9DE-07F9-4B05-8B4E-195F73279767Q37692972-F705AE28-365E-4FA6-B3C4-60DC733091C1Q38152661-4C696BF6-F0B8-456A-8C3B-76B17834833EQ38701378-9B135670-EB26-458A-84D5-44F8A1A5BB7FQ38703578-8E4720CA-DF41-490C-B084-1D100E545862Q39410442-1BAFB3E4-E05B-4E8E-AB00-668CDA50ADCCQ40325984-FCCA58B0-646C-4884-AB79-A58EC67824BBQ40874216-0FB684F4-F450-49E8-957F-5CFD9C3F09B5Q43242467-1A090F15-34A3-4D9E-A08D-92A00E54093BQ47666739-501A4AF8-C228-490F-A85C-8DA17C99550F
P2860
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 May 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
@en
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
@nl
type
label
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
@en
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
@nl
prefLabel
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
@en
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
@nl
P2093
P2860
P1476
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
@en
P2093
Andrew N Freedman
Timothy S McNeel
Worta McCaskill Stevens
P2860
P2888
P304
P356
10.1007/S10549-012-2089-2
P407
P50
P577
2012-05-24T00:00:00Z